Literature DB >> 27621494

New Antilipid Drugs: Do the Known Benefits Justify the Expense?

.   

Abstract

Year:  2016        PMID: 27621494      PMCID: PMC5008430          DOI: 10.4212/cjhp.v69i4.1580

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


× No keyword cloud information.
  13 in total

Review 1.  Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference.

Authors:  G B John Mancini; Steven Baker; Jean Bergeron; David Fitchett; Jiri Frohlich; Jacques Genest; Milan Gupta; Robert A Hegele; Dominic Ng; Janet Pope
Journal:  Can J Cardiol       Date:  2011 Sep-Oct       Impact factor: 5.223

2.  Predicting the Overuse of PCSK-9 Inhibitors.

Authors:  Rene Rodriguez-Gutierrez; Nilay D Shah; Victor M Montori
Journal:  JAMA       Date:  2015-11-10       Impact factor: 56.272

Review 3.  Statin-Associated Autoimmune Myopathy.

Authors:  Andrew L Mammen
Journal:  N Engl J Med       Date:  2016-02-18       Impact factor: 91.245

Review 4.  2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Authors:  Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2016-04-01       Impact factor: 24.094

5.  Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Authors:  Gregory G Schwartz; Laurence Bessac; Lisa G Berdan; Deepak L Bhatt; Vera Bittner; Rafael Diaz; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Matthew T Roe; Tyrus Rorick; William J Sasiela; Cheerag Shirodaria; Michael Szarek; Jean-François Tamby; Pierluigi Tricoci; Harvey White; Andreas Zeiher; Philippe Gabriel Steg
Journal:  Am Heart J       Date:  2014-08-07       Impact factor: 4.749

Review 6.  Canadian Cardiovascular Society position statement on familial hypercholesterolemia.

Authors:  Jacques Genest; Robert A Hegele; Jean Bergeron; James Brophy; Andre Carpentier; Patrick Couture; Jean Davignon; Robert Dufour; Jiri Frohlich; Daniel Gaudet; Milan Gupta; Preetha Krisnamoorthy; John Mancini; Brian McCrindle; Paolo Raggi; Isabelle Ruel; Julie St-Pierre
Journal:  Can J Cardiol       Date:  2014-10-02       Impact factor: 5.223

7.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

Review 8.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

Review 9.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.

Authors:  Jeffrey A Tice; Dhruv S Kazi; Steven D Pearson
Journal:  JAMA Intern Med       Date:  2016-01       Impact factor: 21.873

Review 10.  Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.

Authors:  Nathalie Bergeron; Binh An P Phan; Yunchen Ding; Aleyna Fong; Ronald M Krauss
Journal:  Circulation       Date:  2015-10-27       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.